PRESS-RELEASE ·Filed Aug 7, 2026
Press release: earnings
Actionable Insight • Neutral
Monitor the upcoming earnings release on August 14 for financial results and corporate update. No immediate trading catalyst from this filing; the stock remains a micro-cap with a history of negative earnings and poor post-filing performance.
Latest settled — T+20d
QNRX ▲ +51.57% at T+20d
NEUTRAL call ✓ call won +51.57% · α vs SPY +51.96% · entry $4.79 → $7.26
Latest observation: T+49 -1.44% FF3 residual α
T+1d
+11.90%
call +11.90% · α +11.93%
$5.36
settled 2mo ago
T+5d
+6.26%
call +6.26% · α +5.86%
$5.09
settled 2mo ago
T+20d
+51.57%
call +51.57% · α +51.96%
$7.26
settled 6w ago
T+60d
—
call — · α —
—
in 14d
Price Chart
Loading chart...
Executive Summary
Quoin Pharmaceuticals announced it will release Q2 2026 financial results and provide a corporate update on August 14, 2026, before market open. This is a routine earnings date announcement with no financial data or guidance disclosed.
Key Facts
- Quoin Pharmaceuticals will release Q2 2026 financial results on August 14, 2026 before market open.
- No financial results, guidance, or operational updates were provided in this announcement.
Financial Impact
Not specified
Risk Factors
- Micro-cap biotech with negative EPS history; stock has underperformed historically with a 10% win rate at T+20.
- No revenue or near-term catalysts disclosed; cash runway and pipeline progress remain key uncertainties.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341084 |
14 reports for QNRX
50% Hit rate best @ T+5▲ +18.63%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
Showing 10 of 14
US Market Status
Market Closed — Opens in 5h 50m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access